BioXcel Therapeutics, Inc.

NasdaqCM:BTAI Rapport sur les actions

Capitalisation boursière : US$26.2m

BioXcel Therapeutics Gestion

Gestion contrôle des critères 2/4

BioXcel Therapeutics' CEO is Vimal Mehta, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $4.73M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $34.51K. The average tenure of the management team and the board of directors is 7.1 years and 6.3 years respectively.

Informations clés

Vimal Mehta

Directeur général

US$4.7m

Rémunération totale

Pourcentage du salaire du PDG21.2%
Durée du mandat du directeur général7.5yrs
Propriété du PDG0.1%
Durée moyenne d'occupation des postes de direction7.1yrs
Durée moyenne du mandat des membres du conseil d'administration6.3yrs

Mises à jour récentes de la gestion

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Recent updates

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

Aug 28

Analyse de la rémunération des PDG

Comment la rémunération de Vimal Mehta a-t-elle évolué par rapport aux bénéfices de BioXcel Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$153m

Dec 31 2023US$5mUS$1m

-US$179m

Sep 30 2023n/an/a

-US$212m

Jun 30 2023n/an/a

-US$203m

Mar 31 2023n/an/a

-US$187m

Dec 31 2022US$5mUS$944k

-US$166m

Sep 30 2022n/an/a

-US$137m

Jun 30 2022n/an/a

-US$122m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$9mUS$917k

-US$107m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$100m

Mar 31 2021n/an/a

-US$94m

Dec 31 2020US$10mUS$890k

-US$82m

Sep 30 2020n/an/a

-US$69m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$459k

-US$33m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$22m

Dec 31 2018US$702kUS$423k

-US$19m

Sep 30 2018n/an/a

-US$15m

Jun 30 2018n/an/a

-US$11m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$284kUS$147k

-US$5m

Rémunération vs marché: Vimal's total compensation ($USD4.73M) is above average for companies of similar size in the US market ($USD655.02K).

Rémunération et revenus: Vimal's compensation has increased whilst the company is unprofitable.

PDG

Vimal Mehta (63 yo)

7.5yrs

Titularisation

US$4,731,147

Compensation

Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Vimal Mehta
Founder7.5yrsUS$4.73m0.13%
$ 34.5k
Javier Rodriguez
Senior VP3.8yrsUS$1.12m0.058%
$ 15.3k
Richard Steinhart
Senior VP & CFO7.1yrsUS$404.00k0.050%
$ 13.0k
Frank Yocca
Senior VP & Chief Scientific Officer7.4yrsUS$1.15m0.069%
$ 18.2k
Vincent O'Neill
Executive VP and Chief of Product Development & Medical Officer7.3yrsUS$510.17k0.048%
$ 12.6k
Chetan Lathia
Senior VP and Head of Translational Medicine2.3yrspas de donnéespas de données
Robert Risinger
Chief Medical Officer - Neuroscience2.8yrspas de donnéespas de données

7.1yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Gestion expérimentée: BTAI's management team is seasoned and experienced (7.1 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Vimal Mehta
Founder7.6yrsUS$4.73m0.13%
$ 34.5k
Steven Paul
Member of Advisory Boardno datapas de donnéespas de données
Peter Mueller
Independent Chairman & Lead Director7.6yrsUS$367.33k0.57%
$ 149.6k
Alan Breier
Member of Clinical Advisory Board6.3yrspas de donnéespas de données
Thomas Laughren
Member of Clinical Advisory Board5.8yrspas de donnéespas de données
Maurizio Fava
Member of Clinical Advisory Board5.8yrspas de donnéespas de données
Stephen Marder
Member of Clinical Advisory Board6.3yrspas de donnéespas de données
Sheldon Preskorn
Member of Clinical Advisory Board6.3yrspas de donnéespas de données
John Krystal
Member of Clinical Advisory Board5.8yrspas de donnéespas de données
Sandeep Laumas
Independent Director7.2yrsUS$329.83k0%
$ 0
Sheila Gujrathi
Member of Advisory Boardno datapas de donnéespas de données
George Grossberg
Member of Clinical Advisory Board6.3yrspas de donnéespas de données

6.3yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: BTAI's board of directors are considered experienced (6.3 years average tenure).